Today: 19 July 2026
Browse Category

NASDAQ:TNXP 16 August 2025 - 15 May 2026

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule into major depressive disorder, and watched its stock price explode more than 10,000% over the last year. Tonix Pharmaceuticals Holding Corp.+2Fintel+2
TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

Shares of the small-cap biotech closed around $14.29 on November 25, 2025, down roughly 11% on the session, putting the stock well below its recent highs despite a fresh U.S. FDA green light to advance a new depression treatment into Phase 2 trials. TNXP now trades near the lower end of its volatile 52‑week range of $6.76 to $130.00, with a market capitalization of about $168 million. StockAnalysis
25 November 2025
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix Pharmaceuticals Holding Corp.+2Investing.com+2
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Sources: Key information and quotes in this report are sourced from recent Reuters news dispatches, official press releases, and expert commentary in credible outlets. For full details and further reading, please see the linked sources reuters.com reuters.com reuters.com reuters.com abcnews.go.com abcnews.go.com reuters.com reuters.com sciencedaily.com sciencedaily.com fiercehealthcare.com techstartups.com, among others. Each link corresponds to the original announcement or publication reporting the development in question. This roundup captures the major biotech, pharmaceutical, medical, and health news from August 17–18, 2025, highlighting the continuing innovations and challenges in the health sciences world. Let’s stay tuned as these stories evolve.
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links:
Go toTop